Drugs / Recombinant Human Insulin Growth Factor 1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01777542 Comparator | Jan 2013 → Jul 2016 | Rett syndrome | Boston Children's Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Insulin Growth Factor 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01777542 ↗ |
| Known as | rhIGF-1 | “Recombinant Human Insulin Growth Factor 1 (rhIGF-1)” NCT01777542 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human IGF-1” NCT01777542 ↗ |
| Route | Subcutaneous | “Subjects will receive twice daily subcutaneous injections of IGF-1.” NCT01777542 ↗ |